Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES)

International Journal of Pharmaceutics

Volumn 431, Issue 1-2, 2012, Pages 222-229

  Siddiqui, Akhtar ^a   Gupta, Vineet ^a   Liu, Yong Yu ^a   Nazzal, Sami ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Drug delivery; Gene delivery; Multidrug resistance; Oligonucleotide; Solid lipid nanoparticles

Indexed keywords

DOXORUBICIN; ELECTROLYTE; NANOPARTICLE; OLIGONUCLEOTIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG RELEASE; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OVARY CANCER; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; CETRIMONIUM COMPOUNDS; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; FATTY ALCOHOLS; FEMALE; HUMANS; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS;

EID: 84861333837     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.04.050     Document Type: Article

References (35)

1. Z. Bacso, H. Nagy, K. Goda, L. Bene, F. Fenyvesi, J. Matkó, and G. Szabó Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein Cytometry Part A 61A 2004 105 116
2. M.C. Cabot, A.E. Giuliano, T.Y. Han, and Y.Y. Liu SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells Cancer Res. 59 1999 880 885
3. C.H. Choi ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal Cancer Cell Int. 5 2005
4. X. Dong, C.A. Mattingly, M.T. Tseng, M.J. Cho, Y. Liu, V.R. Adams, and R.J. Mumper Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP Cancer Res. 69 2009 3918 3926
5. G. Dumortier, J.L. Grossiord, F. Agnely, and J.C. Chaumeil A review of poloxamer 407 pharmaceutical and pharmacological characteristics Pharm. Res. 23 2006 2709 2728
6. M.M. Gottesman Mechanisms of cancer drug resistance Annu. Rev. Med. 53 2002 615 627
7. V. Gouaze-Andersson, and M.C. Cabot Glycosphingolipids and drug resistance Biochim. Et. Biophys. Acta (BBA): Biomembr. 1758 2006 2096 2103
8. V. Gouaze-Andersson, and M.C. Cabot Glycosphingolipids and drug resistance Biochim. Biophys. Acta 1758 2006 2096 2103
9. V. Gouaze, Y.Y. Liu, C.S. Prickett, J.Y. Yu, A.E. Giuliano, and M.C. Cabot Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs Cancer Res. 65 2005 3861 3867
10. V. Gouaze, J.Y. Yu, R.J. Bleicher, T.Y. Han, Y.Y. Liu, H. Wang, M.M. Gottesman, A. Bitterman, A.E. Giuliano, and M.C. Cabot Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy Mol. Cancer Ther. 3 2004 633 639
11. R.W. Korsmeyer, R. Gurny, E. Doelker, P. Buri, and N.A. Peppas Mechanisms of solute release from porous hydrophilic polymers Int. J. Pharm. 15 1983 25 35
12. Y.C. Li, M.J. Park, S.K. Ye, C.W. Kim, and Y.N. Kim Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents Am. J. Pathol. 168 2006 1107 1118 (quiz 1404-1105)
13. Y.Y. Liu, V. Gupta, G.A. Patwardhan, K. Bhinge, Y. Zhao, J. Bao, H. Mehendale, M.C. Cabot, Y.T. Li, and S.M. Jazwinski Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling Mol. Cancer 9 2010 145
14. Y.Y. Liu, T.Y. Han, A.E. Giuliano, and M.C. Cabot Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells J. Biol. Chem. 274 1999 1140 1146
15. Y.Y. Liu, T.Y. Han, A.E. Giuliano, and M.C. Cabot Ceramide glycosylation potentiates cellular multidrug resistance FASEB J. 15 2001 719 730
16. Y.Y. Liu, T.Y. Han, A.E. Giuliano, N. Hansen, and M.C. Cabot Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance J. Biol. Chem. 275 2000 7138 7143
17. Y.Y. Liu, T.Y. Han, J.Y. Yu, A. Bitterman, A. Le, and A.E. Giuliano Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells J. Lipid Res. 45 2004 933 940
18. Y.Y Liu, J.Y. Yu, D. Yin, G.A. Patwardhan, V. Gupta, Y. Hirabayashi, W.M. Holleran, A.E. Giuliano, S.M. Jazwinski, V. Gouaze-Andersson, D.P. Consoli, and M.C. Cabot A role for ceramide in driving cancer cell resistance to doxorubicin FASEB J. 22 2008 2541 2551
19. A. Lucci, T.Y. Han, Y.Y. Liu, A.E. Giuliano, and M.C. Cabot Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells Cancer 86 1999 300 311
20. P. Ma, X. Dong, C.L. Swadley, A. Gupte, M. Leggas, H.C. Ledebur, and R.J. Mumper Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia J. Biomed. Nanotechnol. 5 2009 151 161
21. R.H. Müller, K. Mäder, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
22. E. Norris-Cervetto, R. Callaghan, F.M. Platt, R.A. Dwek, and T.D. Butters Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells J. Biol. Chem. 279 2004 40412 40418
23. G.A. Patwardhan, Q.J. Zhang, D. Yin, V. Gupta, J. Bao, C.E. Senkal, B. Ogretmen, M.C. Cabot, G.V. Shah, P.W. Sylvester, S.M. Jazwinski, and Y.Y. Liu A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis PLoS ONE 4 2009 e6938
24. M. Pérez-Sayáns, J.M. Somoza-Martín, F. Barros-Angueira, P.G. Diz, J.M.G. Rey, and A. García-García Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases Cancer Lett. 295 2010 135 143
25. E. Saltiel, and W. McGuire Doxorubicin (adriamycin) cardiomyopathy West J. Med. 139 1983 332 341
26. A. Siddiqui, G.A. Patwardhan, Y.Y. Liu, and S. Nazzal Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells Int. J. Pharm. 400 2010 251 259
27. J.M. van Den Elsen, D.A. Kuntz, F.J. Hoedemaeker, and D.R. Rose Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein Proc. Natl. Acad. Sci. U.S.A. 96 1999 13679 13684
28. G. van Meer, J. Wolthoorn, and S. Degroote The fate and function of glycosphingolipid glucosylceramide Philos. Trans. R. Soc. Lond. B Biol. Sci. 358 2003 869 873
29. M. Wang, and M. Thanou Targeting nanoparticles to cancer Pharmacol. Res. 62 2010 90 99
30. H.L. Wong, R. Bendayan, A.M. Rauth, Y. Li, and X.Y. Wu Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles Adv. Drug Deliv. Rev. 59 2007 491 504
31. H.L. Wong, R. Bendayan, A.M. Rauth, and X.Y. Wu Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers J. Pharm. Sci. 93 2004 1993 2008
32. H.L. Wong, R. Bendayan, A.M. Rauth, and X.Y. Wu Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer J. Control. Release 116 2006 275 284
33. H.L. Wong, R. Bendayan, A.M. Rauth, H.Y. Xue, K. Babakhanian, and X.Y. Wu A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system J. Pharmacol. Exp. Ther. 317 2006 1372 1381
34. H.L. Wong, A.M. Rauth, R. Bendayan, J.L. Manias, M. Ramaswamy, Z. Liu, S.Z. Erhan, and X.Y. Wu A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells Pharm. Res. 23 2006 1574 1585
35. S. Ye, D.P. MacEachran, J.W. Hamilton, G.A. O'Toole, and B.A. Stanton Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif Am. J. Physiol. Cell Physiol. 295 2008 C807 C818